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2 
Abstract 28 
The species B human adenoviruses (short Ad) infect cells upon attaching to CD46 or 29 
desmoglein-2 (DSG-2) by one or several of their twelve fiber knob trimers (FK).  To 30 
test whether DSG-2 and CD46 simultaneously serve as virus receptors for Ad3, we 31 
performed individual and combined CD46/DSG-2 loss-of-function studies in human 32 
lung A549 and 16HBE14o cells.  Our results suggest that in these cells, DSG-2 33 
functions as major attachment receptor for Ad3, whereas CD46 exerts a minor 34 
contribution to virus attachment and uptake in the range of ~ 10%.  However, in other 35 
cells the role of CD46 may be more pronounced depending on, e.g., the expression 36 
levels of the receptors.  To test if avidity allows Ad3/7 to use CD46 as receptor, we 37 
performed gain-of-function studies in rodent cells.  The cell surface levels of 38 
ectopically expressed CD46 in CHO or human M010119 melanoma cells lacking 39 
DSG-2 positively correlated with Ad3/7 infections, while Ad11/35 infections depended 40 
on CD46 but less on CD46 levels.  Antibody cross-linked soluble CD46 blocked 41 
Ad3/7/11/35 infections, while soluble CD46 alone blocked Ad11/35 but not Ad3/7.  42 
Soluble Ad3/7-FKs poorly inhibited Ad3/7 infection of CHO-CD46 cells, illustrating 43 
that Ad3/7-FKs bind with low affinity to CD46.  This was confirmed by Biacore 44 
plasmon resonance studies.  Ad3/7 FK binding to immobilized CD46 at low density 45 
was not detected, unlike Ad11/35-FK.  At higher CD46 densities, however, Ad3/7-FK 46 
bound to CD46 with only 15-fold higher dissociation constants than Ad11/35-FK.  47 
These data show that an avidity mechanism for Ad3/7 binding to CD46 leads to 48 
infection of CD46-positive cells.   49 
50 
3 
Introduction 51 
Human Adenoviridae comprise 55 types, classified into seven species, A to G 52 
(http://www.vmri.hu/~harrach/AdVtaxlong.htm), based on genome sequence 53 
comparison, hemagglutination and additional features.  The B1 viruses Ad3, Ad7, 54 
Ad16, Ad21, Ad50 (short Ad3/7/16/21/50) predominantly infect the upper respiratory 55 
tract, whereas the B2 viruses Ad11/14/34/35 are associated with kidney and urinary 56 
tract infections with fatal outcome in immune-compromised patients (30, 54, 68).  57 
Recent epidemiological reports described the reemergence of several of these virus 58 
types associated with outbreaks of respiratory disease (7, 32, 39, 77).  The tropism of 59 
species B viruses is broader than that of the C species, and includes cancer cells, 60 
dendritic cells and hematopoietic stem cells.  This feature makes the B species 61 
interesting vectors for gene therapy and vaccination approaches (52).  62 
Ads attach to their host cells by binding of the trimeric fiber protein to a cellular 63 
surface receptor.  The fiber protein consists of a tail for anchorage to the penton 64 
base, a shaft of variable length, and a globular fiber knob (FK).  The latter is 65 
responsible for the binding of the virus particle to a primary attachment receptor (43).  66 
Species B Ads bind different cell surface receptor(s) than most of the other species 67 
members (76).  Two receptors have been identified, CD46 for Ad11 (57), Ad35 (15) 68 
and Ad3 (60), and species D Ad37 and Ad49 (31, 74), and desmoglein 2 (DSG-2) for 69 
Ad3/7/11/14 (69, 70).  If CD46 functions as an attachment receptor for all species B 70 
types has been controversial.  Virus competition, CD46 antibody blocking, and siRNA 71 
knock down of CD46 experiments suggested that more than one receptor exists for 72 
species B Ads (15, 19, 37, 56, 57, 60, 67).  It was suggested that all species B Ads 73 
except Ad3/7 would utilize CD46, and all serotypes including Ad3/7 would bind to a 74 
second, common receptor (sBAR) (37, 56).  Another group proposed an alternative 75 
classification, where group I members (Ad16/21/35/50) would almost exclusively use 76 
CD46, while group II members (Ad3/7/14) would not use CD46 but DSG-2, and the 77 
only member of group III (Ad11p) would be able to use both receptors (67, 70).  Both 78 
classifications contrast, however, with findings by others, who reported functional 79 
utilization of CD46 by Ad3 and Ad7 in rodent cells ectopically expressing CD46 (13, 80 
14, 20, 40, 60, 61).    81 
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Affinity analysis of monovalent interactions of different species B FKs to CD46 SCR I-82 
II revealed a broad range of affinities, with similar dissociation constants (KD) for 83 
Ad11 and Ad35-FK (Ad11/35-FK) in the range of 5 to 19 nM, but strongly increased 84 
KD values of 284 nM for Ad21-FK and 437 nM for Ad16-FK, and an about 2,000-fold 85 
reduced affinity for both, Ad7-FK and Ad14-FK to CD46 SCR I-II, compared to Ad11-86 
FK (10, 47, 48).  The crystal structures of FKs for Ad3 (11), Ad35 (46, 71), Ad16 (47), 87 
and Ad7/14 (48) have revealed a generally conserved overall fold and trimeric 88 
organization.  Interestingly, the different FKs have low sequence identity, especially 89 
at the surface loops, which mediate binding to CD46, as indicated by co-crystal 90 
structures of CD46 SCR I-II with Ad11-FK (49), or Ad21-FK (10).  These crystal 91 
structures also suggested interactions of the trimeric fiber molecule with three CD46 92 
molecules, albeit involving substantial differences in the number and types of 93 
contacts.  The binding surface on CD46 SCR I-II for Ad11-FK comprises a large 94 
continuous area of 1,681 Å2, with three main contact points composed of fiber knob 95 
DG, HI and the IJ loop residues.  A more recent co-crystal structure of Ad11-FK in 96 
complex with an extended CD46 SCR I-IV confirmed the involvement of the DG and 97 
HI loops, but not of the IJ loop (50).  Together, this wealth of structural evidence 98 
indicates that there are no central binding motifs among species B Ads, which would 99 
explain the macroscopic observations that there is a wide range of affinities for CD46 100 
between the different FKs (10, 47, 71). 101 
Here we tested two hypotheses, first that DSG-2 and CD46 simultaneously serve as 102 
receptors for Ad3, and second, that avidity effects allow the low affinity CD46-binders 103 
Ad3/7-FK to attach to CD46, and thereby grant these viruses to use CD46 as an 104 
entry receptor.  We performed loss-of-function studies in human A549 and 105 
16HBE14o lung cells and showed that DSG-2 functions as a major attachment 106 
receptor for Ad3, whereas CD46 exerts a minor contribution in the range of ~ 10% to 107 
virus attachment and up-take. Gain-of-function in CD46-negative CHO or CD46-low 108 
human melanoma cells both negative for DSG-2 demonstrated that Ad3/7 infections 109 
increased with increasing levels of ectopic CD46.  We further showed that 110 
multimerized soluble CD46 blocked Ad3/7 infections, and that Ad3/7-FK reduced 111 
Ad3/7 infections in A549 cells expressing high levels of CD46.  Finally, biosensor 112 
5 
measurements demonstrated that affinities of Ad3/7-FKs to immobilized CD46 113 
increased at high receptor densities.  These data argue that CD46 is a receptor for all 114 
species B adenoviruses if present at sufficient levels, and may function together with 115 
or separately from DSG-2.  116 
117 
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Materials and Methods 118 
Viruses and cells.   119 
Ad3CMV-eGFP, Ad7CMV-eGFP Ad11CMV-eGFP and Ad35CMV-eGPF containing 120 
the CMV-eGFP expression cassette in the deleted E1 region were prepared at 121 
concentrations of 7.1x1011, 1.6x1011, 6.6x1011 1.3x1012 virus particles (vp)/ml and 122 
have been described previously (13, 14).  Ad3 (prototype strain GB), Ad7 (prototype 123 
strain Gomen), Ad11p and Ad35 (Holden strain) were radio labeled as described 124 
(14).  Specific activities were in the range of 2.6 x 10-5 to 4.9 x 10-5 cpm/vp.  Likewise, 125 
Ad2, Ad3 and Ad35 were labeled with atto488 (Atto-tec, Germany) similar as 126 
described (65). 127 
Chinese hamster cell lines CHO-K1 and CHO-15B6 (containing a mutation in the N-128 
acetylglucosamininyl-transferase 1), the human 293T and 911 embryonic kidney 129 
cells, and the A549 lung carcinoma cells were grown in Dulbecco’s modified Eagle’s 130 
medium (DMEM) plus 8% fetal bovine serum (FBS).  The human 16HBE14o 131 
bronchial epithelial cells (17) and the primary human melanoma cell cultures 132 
M010119 (55) were grown in RPMI 1640 plus 8% FBS as described earlier.  CHO-133 
CD46 cell lines stably expressing the BC1 splice isoform were generated as 134 
described for the BHK-CD46 cells (60).  For stable transfection of CHO-15B6 and 135 
M010119 cells with the N-terminal eGFP-tagged CD46-encoding cDNA (eGFP-136 
CD46), a PCR-amplified CD46 sequence was cloned into pcDNA3.1-CARSP-eGFP-137 
CAR (5), replacing the mature Coxsackie virus B and Ad receptor (CAR) cDNA.  In 138 
the resulting construct, the 19 amino acid residues of the human CAR signal peptide 139 
sequence were followed by two spacer residues, 239 residues of eGFP, ten 140 
additional spacer residues, and 344 residues of the mature CD46 BC1 isoform.  To 141 
avoid eGFP-induced dimerization of the tagged CD46, an A206K mutant of eGFP 142 
was utilized (75).  Following selection in DMEM plus 8% FBS and 0.8 mg/ml G418, 143 
individual clones were picked and screened giving rise to the limiting dilution clone 144 
CHO-eGFP-CD46#33.5.  To generate human melanoma M010119 and lung 145 
carcinoma A549 cells expressing eGFP-CD46, a lentiviral expression system was 146 
used.  For this, the eGFP-CD46 cDNA was subcloned into the lentiviral pBlasti vector 147 
(27), and lentiviral vectors were generated by transient transfection in 293T cells.  148 
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M010119 and A549 cells transduced with lentiviral vector pBlasti-eGFP-CD46 were 149 
selected in blasticidin-containing medium at 4 µg / ml.  Resulting bulk cultures 150 
M010119-eGFP-CD46#8 and A549-eGFP-CD46#2 revealed homogenous CD46 151 
expression.   152 
 153 
Immune reagents.   154 
Cytofluorometric analysis, CD46-specific antibodies and secondary fluorochrome 155 
conjugates have been described previously (14, 60).  The hybridoma cell line 156 
secreting the MCI20.6 anti-CD46 antibody was a generous gift from Denis Gerlier 157 
(42).  Monoclonal 8E5- and 6D8-anti desmoglein 2 were purchased from Santa Cruz 158 
Inc., and goat anti-human IgG-Fc from BETHYL Laboratories Inc.. 159 
 160 
Virus binding and transduction assays.   161 
Binding experiments including radio-labeled Ads were performed as described 162 
previously (14).  For binding experiments using atto488-labeled viruses, the same 163 
procedure was used, except cells were analyzed by cytofluorometric means.  For 164 
eGFP expression analysis, triplicates of 105 cells were seeded in 12-well plates.  165 
After incubation for 3 h at 37°C, 5% CO2, the cells were infected with recombinant 166 
eGFP-expressing Ads at virus concentrations of 10, 100, or 1,000 vp/cell.  Medium 167 
was replaced 5 h p.i., and cells were analyzed two days p.i. by flow cytometric 168 
analysis (Cytomics FC 500; Beckman Coulter).   169 
For FK competition experiments, cells were seeded in triplicate 12-well plates and 170 
were allowed to adhere as above.  After 3 h, the medium was removed and the cells 171 
were washed with cold PBS.  For blocking with FK proteins, serial 5-fold dilutions of 172 
the different FKs were prepared in PBS, resulting in concentrations of 5,000, 1,000, 173 
200, 40, and 8 ng/ml.  500 µl of FK dilutions were added to the cells and incubated 174 
for 1 h on ice under constant shaking.  Subsequently, eGFP-encoding Ad vectors 175 
were added and incubated for 1 h.  The amount of virus added was optimized in 176 
preceding experiments and was adjusted such that for all five eGFP-expressing 177 
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vectors, similar reporter expression levels in the range of 100 to 500 were obtained 178 
by FACS measurement.  Thus, for A549 cell transduction, Ad3-, 5-, 7-, 11-, and 35-179 
eGFP vectors were used at 14,800, 2,825, 8,200, 1,314 and 2,540 vp/cell, 180 
respectively.  For CHO-CD46#2, the virus input was adjusted to 29,600, 2,825, 181 
8,200, 657 and 1,088 vp/cell, respectively.  The cells were washed twice with cold 182 
PBS and were returned to standard cell culture conditions.  Analysis of cells was 183 
performed two days p.i., as described above.  For competition experiments including 184 
recombinant CD46ex-huFc, FK proteins were replaced with the indicated 185 
concentrations of CD46ex-huFc or CARex-huFc.  In case of including cross-linking of 186 
CD46ex-huFc and CARex-huFc, the adapter proteins were pre-incubated on ice with 187 
goat anti-human IgG antibody for 30 min before adding to the cells.  Specific siRNAs 188 
for CD46 (15) and DSG-2 (70) were synthesized by Microsynth (Switzerlandand) and 189 
scrambled siRNA control was obtained from Qiagen.  siRNA transfections were 190 
performed with Lipofectamine 2000 (Invitrogen) for A549 cells and Interferin 191 
(Polyplus) for 16HBE14o cells.  Knock down cells were infected with recombinant 192 
eGFP-expressing Ads at virus concentrations of 500 vp/cell.  Statistical evaluation 193 
was performed using Student’s t test. 194 
 195 
Generation of recombinant soluble Ad receptor and fiber knob proteins.  196 
Production of the soluble CD46ex-huFc and CARex-huFc has been described earlier 197 
(12, 60).  CD46ex-huFc comprises 295 amino acids of the mature extracellular 198 
domain including all SCR I-IV domains, the STP of BC1, plus the short region of 199 
unknown function, fused to the 232 amino acids of the human IgG1-Fc domain 200 
including hinge, CH2 and CH3 regions.  Production of CD46-SCR I-II consisting of 201 
145 amino acids, including a N-terminal his-tag and spacer, has been described in 202 
(14).  CARex-huFc protein comprises the extracellular domain of CAR fused to the 203 
human IgG1-Fc domain.  The five recombinant FKs derived from Ad3, 5, 7, 11, and 204 
35 were produced using the Bac-to-Bac baculovirus expression system (pFastBac, 205 
Stratagene).  All FKs contained a N-terminal 6xhis-tag used for single step Ni-NTA-206 
agarose affinity chromatography, followed by the recognition site for TEV protease.  207 
FK comprised the fiber sequence residues 114 to 319 for Ad3 (NCBI gene bank ID 208 
9 
(GI) 78059423), 384 to 581 for Ad5 (GI: 56160559), 126 to 325 for Ad7 (GI: 209 
51173336), 126 to 325 for Ad11 (GI: 56160807), and 126 to 323 for Ad35 (GI: 210 
56160945).  Calculated weights of the FK monomer/trimers were 26.28/78.85, 211 
24.98/74.95, 25.63/76.89, 25.90/77.71, and 25.50/76.50 kDa for FK of Ad3, 5, 7, 11, 212 
and 35, respectively. 213 
 214 
Surface plasmon resonance analysis for kinetics/affinity between CD46 and 215 
Ad-FKs   216 
Surface plasmon resonance (SPR) experiments were performed on a Biacore T100 217 
system (GE Healthcare) at 25°C equipped with CM5 sensor chips.  All reagents 218 
including amine-coupling kit, HBS-P+ and CM5 chips were purchased from Biacore 219 
(GE Healthcare).  Buffer HBS-P+ pH 7.4 (10 mM HEPES, pH 7.4, 150 mM NaCl, 220 
0.05% (v/v) Surfactant P20) was used as running buffer for the entire measurement.  221 
Each CM5 chip contained four flow cells, designated Fc1-Fc4.  The Fc2/Fc4 were 222 
used to immobilize the CD46ex-huFc ligand, while Fc1/Fc3 were used to immobilize 223 
the CARex-huFc ligand.  The immobilization procedure included three steps; surface 224 
activation by using a 1:1 mix of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 225 
in water (EDC) and 0.1 M N-hydroxysuccinimide in water (NHS) for 420 s with a flow 226 
rate of 5 µl/min, immobilization of 0.12 µM ligands in 10 mM sodium acetate pH 4.0 227 
buffer, and deactivation of excess reactive groups by using 1 M ethanolamine-HCl 228 
pH 8.0 for 420 s with a flow rate of 5 µl/min.  Following completion of immobilization, 229 
the sensor chip was conditioned three times with 50 mM NaOH to stabilize the 230 
surface.  For initial binding assays, Ad3-, 11- and 35-FK analytes were injected at 231 
18.75 and 150 nM, and Ad7-FK at 11.07 and 88.59 nM in HBS-P+ buffer at either 30 232 
or 50 μl/min using a contact time of 240 or 280 s.  For kinetic studies, Ad3, 7, 11 and 233 
35 FK analytes were injected at 0.27, 0.82, 2.47, 7.41, 22.22 and 66.67 nM in HBS-234 
P+ buffer at either 30 or 50 μl/min using a contact time of 300 or 360 s and a 235 
dissociation time of 3,600 s.  After each binding cycle, the CM5 surface chip was 236 
regenerated by injection of 3 M MgCl2 for 30 to 45 s, followed NaOH in a range of 4–237 
50 mM for 20 s.  All analyte concentrations were repeated twice and the obtained 238 
sensograms were corrected by subtracting the data from the reference flow cell and 239 
10 
from blank buffer injections (double referencing).  For details of kinetic and affinity 240 
analysis as well as fitting procedure see supplemental Methods. 241 
242 
11 
Results  243 
 244 
CD46 and Desmoglein 2 simultaneously serve as Ad3 receptor.   245 
To test whether CD46 and DSG-2 simultaneously or additively serve as attachment 246 
receptors, we performed loss-of-function studies in human lung carcinoma A549 247 
cells.  These cells stained positive for CD46 (sFig. 1A) and DSG-2 (sFig. 1B) 248 
expression, revealing arbitrary mean fluorescence intensities (MFI) of 74 and 29, 249 
respectively.  We tested antibodies against CD46, DSG-2 and a mix of both, and 250 
determined their effects on Ad3 and Ad35 binding.  For this, cells were incubated 251 
with 1,000 vp of atto488-labeled wild type Ad3/35 followed by determination of cell-252 
associated viruses by cyto-fluorometric analysis.  When compared to PBS and anti-253 
CAR antibody controls, pre-incubation of A549 cells with the known CD46 blocking 254 
antibody MEM258 (14) gave 13 and 8% reduction of Ad3 binding at the highest 255 
concentration of 20 µg/ml, respectively (Fig. 1A).  This is in agreement with earlier 256 
results reporting inhibition of Ad3 binding to human cells, for example, 40% binding 257 
reduction to human K562 cells (60), or up to 48% inhibition for human 258 
hepatoblastoma HuH-7 cells (67).  Pre-incubation with increasing concentrations of 259 
DSG-2 antibodies on the other side resulted in 47 and 42% reduction of Ad3 binding 260 
at 4 and 40 µg/ml, respectively, which is comparable to the approximately 60% 261 
maximal inhibition reported by Wang et al. using twice the concentration of the same 262 
mix of antibodies used here (70).  Interestingly, when CD46 and DSG-2-specific 263 
antibodies were combined, we noticed a significant additive inhibition resulting in 264 
70% inhibition of Ad3 binding.  In comparison, the high concentrations of CD46 265 
antibody reduced Ad35 binding by 93 and 98%, but the DSG-2 antibody mix had no 266 
significant effects (Fig. 1B).  These results are consistent with the notion that Ad35 267 
uses CD46 but not DSG-2 as an attachment receptor (13, 67). 268 
We next performed siRNA-mediated knock down of CD46, DSG-2 and both 269 
receptors together, and analyzed these cells for virus binding and transduction.  270 
Initial tests for optimizing siRNA concentrations confirmed that best CD46 down-271 
regulation was obtained using a single CD46-specific siRNA at 5 nM, whereas a pool 272 
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of four DSG-2-specific siRNAs each at 5 nM was optimal for DSG-2 protein 273 
downregualtion when measured by cytofluorometric analyses (15, 70).  In five 274 
independent experiments, siRNA-mediated reduction of CD46 was in the range of 74 275 
to 88% with a mean of 82%, when using the CD46-specific siRNA alone, and 67 to 276 
86% with a mean of 77%, when using the CD46-specific siRNA in combination with 277 
DSG-2-specific siRNAs (see Fig. 1C for a representative experiment).  Similarly, 278 
siRNA-mediated reduction of DSG-2 was in the range of 68 to 80% with a mean of 279 
73%, when using the DSG-2 siRNAs alone, and 63 to 82% with a mean of 71%, 280 
when using the DSG-2 siRNAs in combination with the CD46 siRNA.  When binding 281 
of atto-488 labeled Ad3 to these cells was analyzed, we noticed that in CD46 siRNA-282 
only-cells binding was reduced by 28% in the experiment shown in Fig. 1D, whereas 283 
binding of Ad3 to DSG-2 siRNA-only-cells was reduced by 66%.  Similar as for the 284 
antibody blocking experiments, combination of both siRNAs additively reduced Ad3 285 
binding to 77%.  Of note, the additive Ad3 binding reduction was not paralleled by a 286 
reduction of the DSG-2 expression level in the siRNA combination cells, indicating 287 
specificity for CD46.  The range of reduction varied from 3 to 23%, with a mean of 288 
11%.  As for the antibody inhibition experiment, Ad35 attachment was mainly 289 
affected by CD46 but not DSG-2 interference, resulting in 76 and 77% binding 290 
reduction for CD46-only siRNA and CD46 plus DSG-2 siRNAs, respectively.  291 
Attachment of the CAR-binding Ad2 was not affected in these cells, demonstrating 292 
the specificity of the observed virus binding reduction for Ad3/35.   293 
We then used the four different siRNA cells to analyze transduction by Ad5, Ad3 and 294 
Ad35-eGFP reporter viruses. CD46 interference gave no decrease in eGFP 295 
expression for Ad3/5 (Fig. 1E).  However, Ad3-eGFP-mediated expression was 296 
reduced by 71% in DSG-2 siRNA-treated cells and by 82% in DSG-2 plus CD46 297 
siRNA combination cells, revealing a small additive effect of 11% (Fig. 1E).  The 298 
additive reduction in Ad3 infection by siRNA combination cells was reproducibly 299 
significant, and varied from 11 to 17%, with a mean of 13% in 4 of 5 experiments.  It 300 
should be noted here that CD46 down-regulation had a very small effect on the 301 
transduction by Ad35-eGFP.  We therefore repeated this experiment using a chimeric 302 
Ad5 containing the fiber knob and shaft from Ad35 (Ad5-eGFP-FK35), and found a 303 
13 
60% reduction of transgene expression upon CD46 siRNA silencing (data not 304 
shown).  This was similar to data from others using a similar fiber chimeric vector 305 
(15).  As suggested earlier, a possible explanation for these observations includes 306 
that fiber-knob swapped vectors have altered intracellular trafficking or stability (63).  307 
Using the same approach, we also tested human 16HBE14o bronchial epithelial 308 
cells, which are a commonly used model for respiratory epithelial cell infections (17, 309 
35).  These cells revealed about 2-fold lower CD46 (sFig. 1C) and 3-4-fold lower 310 
DSG-2 (sFig. 1D) expression, when compared to A549 cells.  siRNA-mediated 311 
reduction of CD46 and DSG-2 was in average 89 and 91%, respectively, when using 312 
the single-specific siRNA alone or in combination (Fig. 1F).  Binding of atto-488 313 
labeled Ad3 in CD46 was reduced by 20 and 85% in CD46 and DSG-2 siRNA-only-314 
cells, respectively, and combination of both siRNAs additively reduced Ad3 binding to 315 
95% (Fig. 1G).  When using the four different siRNAs cells to analyze transduction by 316 
eGFP reporter viruses, Ad3-eGFP-mediated expression was reduced by 48% in 317 
DSG-2 siRNA-treated cells and by 76% in DSG-2 plus CD46 siRNA combination 318 
cells, revealing an additive effect of 28% (Fig. 1H).   319 
Taken together, our results suggest that A549 and 16HBE14o cells expressing both 320 
DSG-2 and CD46, DSG-2 functions as major attachment receptor for Ad3, whereas 321 
CD46 exerts an accessory role for binding and uptake.  In other human cells, 322 
however, the CD46 contribution may be more pronounced depending, e.g., on the 323 
expression levels of the receptors.  324 
 325 
Increasing ectopic expression of CD46 leads to enhanced transduction of 326 
Ad3/7/11/35 in rodent and human cells.   327 
Avidity effects allow viruses to infect susceptible cells despite somewhat low affinity 328 
to cell surface receptors (22, 73).  We therefore tested if avidity effects occur during 329 
interaction of the Ad3/7 serotypes in CD46-gain of function experiments.  We and 330 
others had shown earlier that rodent cells such as hamster BHK and CHO cells, or 331 
mouse Ltk- and B16 cells stably expressing CD46 become sensitive to infection with 332 
various species B human Ads, including Ad3/7/11/35 (13, 14, 20, 40, 60, 61).  333 
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To address if CD46 needs to be expressed at a certain threshold level to be an Ad3/7 334 
receptor, we generated clonal CHO cells stably expressing different levels of the 335 
CD46 BC1 isoform and compared their binding and transduction for species B 336 
serotypes.  Of note, rodent cells including unmodified CHO were found negative for 337 
Ad3 binding (15, 20, 37, 67, 70 and Fig. 2B)) and they did not stain with a DSG-2 338 
antibody (data not shown), suggesting that they lack expression of DSG-2 or that 339 
hamster DSG-2 is not able to bind human Ad3.  The highest levels of CD46 were 340 
measured in CHO-CD46#2 cells with an arbitrary mean fluorescence intensity (MFI) 341 
of 161, followed by CHO-CD46#1 (MFI of 45), and CHO-CD46#6 (MFI of 33) 342 
(sFig. 1A).  All three CHO clones were derived from CHO-15B6 cells.  Additional 343 
CHO-CD46#RC cells, which were derived from CHO-K1 cells (4) and expressed 344 
similar CD46 levels as CHO-CD46#1 were included as controls in the transduction 345 
study.  These cells gave similar data to CHO-CD46#1 and are not shown here.  We 346 
noticed, however, that the CD46 stably transfected cells had broader expression 347 
ranges than for example human lung carcinoma A549 cells, which had an MFI of 74.  348 
We therefore used the stable CD46 expressing CHO cells at low passage numbers 349 
to ensure comparable expression levels.  Cells were incubated with 1,000 vp of [3H]-350 
thymidine-labeled wild type Ad3/7/11/35 followed by determination of cell-associated 351 
viruses by liquid scintillation counting (Fig. 2A).  CHO-CD46#2 cells expressing the 352 
highest levels of CD46 revealed highest virus binding for all four viruses, followed by 353 
CHO-CD46#1 and CHO-CD46#6 cells, which bound 2-4-fold more virus compared to 354 
parental CHO cells.  Binding of Ad3/7/11 to A549 cells was intermediate compared to 355 
CHO-CD46#2 and CHO-CD46#1 cells, whereas binding of Ad35 was higher to A549 356 
than CHO-CD46#2 cells. 357 
Since binding experiments have a relatively low dynamic range, we performed 358 
transduction experiments using eGFP-expressing vectors. Increasing amounts of 359 
recombinant Ad3/7/11/35 expressing eGFP gave a robust increase of transgene 360 
expression in all four CHO-CD46 cells (including CHO-CD46#RC cells) (Fig. 2B and 361 
Table 1).  At a virus concentration of 1,000 vp/cell, e.g., Ad3-mediated eGFP 362 
expression increased 18-fold in CHO-CD46#6 cells, 55-fold in CHO-CD46#1 cells, 363 
and 192-fold in CHO-CD46#2 cells, when compared to parental CHO cells.  When 364 
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standardized to A549 cells, Ad3-eGFP-mediated transgene expression levels 365 
amounted to 0.24% in parental CHO cells, 19% in CHO-CD46#6 cells (with 2.2-fold 366 
lower CD46 than A549), 60% in CHO-CD46#1 cells (with about 1.5-fold lower CD46 367 
than A549), and 211% in CHO-CD46#2 cells (2.2-fold higher CD46 than A549).  For 368 
better comparison of transduction efficiency, vp/cell concentrations necessary to 369 
reach the arbitrary MFI value of 100 were calculated (Table 1).  These values 370 
showed that highest input of 8,207 Ad3 vp/cell was needed for CHO-CD46#6 cells, 371 
2,597 vp/cell for CHO-CD46#1 cells, and 717 vp/cell for CHO-CD46#2 cells to reach 372 
comparable transduction levels.  Transduction with Ad7 was about 2-fold more 373 
efficient than Ad3 when comparing vp/ml values necessary to reach MFI of 100.  374 
Ad11/35 consistently transduced all tested cells more efficiently than Ad3/7, including 375 
control A549 cells and parental CHO cells.  When standardized to Ad35, Ad3 376 
infection of CHO-CD46#6, #1, #2 and A549 required 27, 16, 4.2 and 2.7-fold higher 377 
vp input to obtain the MFI value of 100, respectively.  For Ad7, these numbers 378 
amounted to 9.5, 7.3, 1.57 and 1.1-fold.  In contrast, Ad11 had a similar transduction 379 
efficacy as Ad35.  Of note, when using Ad5-eGFP in these cells, transduction levels 380 
were within a factor of 2 for the different CD46-expressing clones including the 381 
parental CHO cells. 382 
We also tested whether human melanoma M010119 cells with low CD46 expression 383 
(MFI of 17.8) (sFig. 1E) were increasingly transduced with Ad-eGFP vectors by 384 
increasing CD46 levels.  Stable transfection of these cells (M010119-eGFP-CD46#8) 385 
resulted in about 9-fold higher CD46 expression levels (MFI of 155), compared to the 386 
parental cells.  In this case, an N-terminal eGFP-tagged CD46 BC1 isoform was 387 
used, where the endogenous signal peptide was replaced by the CAR signal peptide, 388 
followed by the eGFP sequence and the sequence of the mature CD46 BC1 isoform.  389 
Of note, the receptor function of the eGFP-tagged CD46 form was retained for all 390 
four species B serotypes tested in M010119-eGFP-CD46#8 cells (Fig. 2C, Table 2).  391 
When using 1,000 vp/cell, M010119-eGFP-CD46#8 cells with the 9-fold higher CD46 392 
level revealed 86, 26, 2.1 and 2.3-fold enhancements of reporter eGFP for 393 
Ad3/7/11/35 mediated transduction, respectively, when compared to parental 394 
M010119 cells.  Determination of vp/cell ratios necessary to reach MFI value of 100, 395 
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revealed 127, 52, 3.1, and 2-fold enhancement of Ad3/7/11/35-mediated 396 
transduction, respectively.  Of note, both, the parental M010119 low-CD46 cells as 397 
well as the M010119-eGFP-CD46#8 high-CD46 cells expressed no DSG-2, when 398 
analyzed by cytofluorometric means (sFig. 1B, F), in contrast to A549 cells, which 399 
expressed high levels of DSG-2.   400 
In summary, ectopic expression of CD46 in rodent cells, or enhanced expression of 401 
CD46 in human cells low in CD46 and negative for DSG-2 resulted in increased 402 
transduction with Ad3/7/11/35 species B serotypes.  Transduction efficacy of Ad3/7 403 
correlated with CD46 density levels in these cells, whereas Ad11 reached a plateau 404 
with the medium CHO-CD46#1 cells and Ad35 was largely independent of the CD46 405 
levels.  This is compatible with the notion that Ad3/7 exhibit a lower affinity for CD46 406 
than Ad11/35, but can compensate the lower affinity by avidity binding. 407 
 408 
Cross-linking of soluble CD46 enhances blocking of Ad3 and Ad7 infection of 409 
CHO-CD46 and A549 cells.   410 
We earlier documented that soluble CD46ex-huFc was at least 100-fold more potent 411 
at blocking Ad11/35 binding to rodent cells expressing CD46, when compared to Ad3 412 
and 7 (13).  To further test the hypothesis that avidity allows Ad3/7 to use CD46 as a 413 
functional receptor, we repeated the virus blocking assays with CD46ex-huFc, but 414 
included this time cross-linked adapter proteins.  We reasoned that antibody-415 
mediated cross-linking of CD46ex-huFc could provide locally more binding sites per 416 
molecule, mimicking the situation on the cell membrane where CD46 can diffuse 417 
freely and form clusters following multivalent binding (1, 9).  418 
When using 50, 500, and 5,000 ng/ml of CD46ex-huFc protein alone, only Ad11-419 
eGFP or Ad35-eGFP mediated transgene expression were significantly reduced in 420 
CHO-CD46#2 or A549 cells (Fig. 3A, B).  In contrast, CD46ex-huFc did not result in 421 
significant reduction of Ad3/7 mediated transgene expression (sFig. 2A, B).  422 
However, when we combined CD46ex-huFc protein at a concentration of 500 ng/ml 423 
with 2-fold increasing amounts of cross-linking goat-anti human Fc antibody, 424 
significant blocking was also achieved for both Ad3 and Ad7-mediated transgene 425 
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expression.  Inhibition followed a precipitin-type curve reaching a plateau in the range 426 
of 500, 1,000 or 2,000 ng/ml of goat anti-human Fc.  Highest blocking for Ad3-eGFP 427 
amounted to 65% in CHO-CD46#2 cells and 83% in A549 cells, and for Ad7-eGFP, 428 
the highest blocking was 77% in both cell types.  We conclude that CD46ex-huFc 429 
multimerization leads to efficient blocking of Ad3/7.  A similarly multimerized complex 430 
consisting of CARex-huFc had no significant effects on Ad3/7 infection, but CARex-431 
huFc inhibited Ad2/5 transduction (12, 38).   432 
 433 
Species B adenovirus fiber knobs cross-compete for CHO-CD46 and A549 434 
transductions 435 
To further characterize affinity differences and receptor usage by species B Ads, we 436 
performed blocking studies with species B Ads and soluble FKs in CHO-CD46#2 and 437 
A549 cells.  CHO-CD46#2 cells do not express DSG-2, unlike human A549 cells.  438 
Virus inhibition assays were performed using five different eGFP-expressing vectors 439 
as readout for binding and infectivity.  For CHO-CD46#2 cells, Ad3/7/11/35-eGFP 440 
inputs of 29,600, 8,200, 657, and 1,088 vp/cell, respectively, were used.  For A549 441 
cells, the virus inputs amounted to 14,800, 8,200, 1,314 and 2,540 vp/cell, and in 442 
addition, for Ad5-eGFP an input of 2,825 was applied.  The virus input concentrations 443 
were chosen such that the unblocked transgene expression values amounted to 444 
fluorescence intensities in the range of about 200, thereby allowing an optimal 445 
dynamic range (not shown).  We assured that FKs of Ad3/7/11/35 were 446 
predominantly present in trimeric form (sFig. 3A, B).  All five Ad FK proteins were 447 
tested in a dose-dependent manner with the highest concentration of 5,000 ng/ml 448 
diluted in a 5-fold dilution series to the lowest concentration of 8 ng/ml (Fig 4A, B and 449 
Table 3).   Specificity of this assay was confirmed by the finding that the species C 450 
Ad5-FK only gave rise to inhibition of Ad5, but not for any of the species B serotypes.  451 
Likewise, species B FKs only inhibited species B serotypes, but not Ad5-eGFP. 452 
The cross-competition assays revealed differences in the capacity of the individual 453 
FKs to compete with species B viruses.  The Ad3/7-FKs on one side, and Ad11/35-454 
FKs on the other side showed similar behavior, which, however, was different in the 455 
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two cell types tested.  In CHO-CD46#2 cells, Ad3/7-FKs elicited at best weak 456 
competition for corresponding and non-corresponding Ad3 and Ad7, and no effect on 457 
non-corresponding Ad11 and Ad35.  This is illustrated by the 40% inhibition of Ad3-458 
eGFP transduction at the highest Ad3-FK concentration of 5,000 ng/ml, and a non-459 
significant 7% inhibition for Ad7-eGFP transduction.  Ad3-FK concentrations 460 
necessary for 50% inhibition (FK-50%) were larger than the highest concentration 461 
available, and could thus not be calculated.  Ad7-FK was more efficient than Ad3-FK, 462 
and using 5,000 ng/ml, 86 and 81% of Ad3/7-mediated eGFP expression was 463 
inhibited, respectively.  FK-50% inhibition values for Ad7-FK were determined to be 464 
169 and 2,690 ng/ml for Ad3/7-mediated transgene expression, respectively.  In 465 
contrast, Ad11/35-FKs led to efficient blocking of all B-type viruses in these cells.  466 
Likewise, Ad35-FK blocking efficiency was in the range of 85 to 97% at 5,000 ng/ml, 467 
and the corresponding FK-50% values were 5, 63, 14 and 26 ng/ml.  468 
The binding inhibition pattern for A549 cells was different than for CHO-CD46#2 469 
cells.  In A549 cells, Ad3/7-FKs efficiently competed for corresponding and non-470 
corresponding Ad3/7 in A549 cells with FK-50% inhibition values of 25 and 23 ng/ml, 471 
respectively (Fig. 4B, Table 3).  With highest concentrations of Ad7-FK, blocking 472 
efficiency of 95 and 87% was obtained for Ad3/7-mediated eGFP expression, 473 
respectively, with FK-50% values of 17 and 31 ng/ml, respectively.  However, as for 474 
CHO-CD46#2 cells, Ad3/7-FKs revealed no effect on non-corresponding Ad11/35 in 475 
A549 cells.  Ad11-FK efficiently blocked all four species B serotypes, with FK-50% 476 
inhibition values of 31, 87, 13, 13 ng/ml, whereas Ad35-FK was less efficient at 477 
inhibiting Ad3 and 7, with FK-50% values of 470, and 4’459 ng/ml, respectively, but 478 
very efficient at inhibiting Ad11 and 35, with FK-50% values of 33 and 5 ng/ml, 479 
respectively. 480 
In summary, blocking studies with Ad3/7-FKs revealed different effects for 481 
corresponding viruses in CHO-CD46 cells or human A549 cells.  In CHO-CD46 cells, 482 
the observed low blocking efficiency confirms the low affinity of the Ad3/7 soluble FK 483 
molecules to CD46.  In contrast, the efficient blocking activity of Ad3/7-FK in A549 is 484 
compatible with our findings that up to 90% of Ad3 binds with a presumable higher 485 
affinity to DSG-2, whereas a minor fraction binds to CD46. 486 
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 487 
Binding and affinity determinations of CD46 to Ad3/7/11/35-FK by surface 488 
plasmon resonance.   489 
To further characterize species B Ad interactions with CD46 we applied biosensor 490 
technology using soluble CD46 and the FKs of Ad3/7/11/35, which were 491 
predominantly present in trimeric form (sFig. 3A, B).  Initial Biacore experiments 492 
using sensor chips had previously been described for immobilized FKs and 493 
monovalent CD46-SCR I-II as soluble analyte thereby avoiding avidity effects of 494 
CD46 (10, 47, 48, 71, 72).  The SCR I-II domain comprised the binding sites for the 495 
FKs (14, 49, 53, 71).  Under these conditions, we determined the affinities of 496 
Ad11/35-FK to CD46-SCR I-II, and found that they were consistent with a 1:1 497 
(monophasic) binding model, where one surface FK monomer interacted with one 498 
soluble CD46-SCR I-II (data not shown).  Ad3/7-FK, however, did not bind to 499 
immobilized CD46-SCR I-II, most likely due to low affinity of their monomers to 500 
CD46-SCRI-II, in agreement with earlier data for Ad7-FK (48).  501 
In a reversed set-up of the SPR measurements we immobilized the extracellular 502 
domain of CD46 fused to human Fc (CD46ex-huFc, see 60) to the flexible dextran 503 
matrix of the sensor chip and used FKs as analytes.  CD46ex-huFc is a disulfide-504 
linked dimer, as suggested by native gel electrophoresis (sFig. 3C, and not shown).  505 
We first tested if different concentrations of immobilized CD46ex-huFc would give 506 
different binding responses for the FKs.  Hereto, flow cell 2 (Fc2) of the CM5 sensor 507 
chip was coated with high density of CD46ex-huFc (2,630 resonance units, RU), and 508 
the control Fc1 with high density of CARex-huFc (3,431 RU).  In a parallel set up, 509 
Fc4 was coated with low surface density of CD46ex-huFc (345 RU), and Fc3 with low 510 
density of CARex-huFc (278 RU).  From the sensograms of Ad3/7/11/35-FK binding 511 
to CD46ex-huFc we noticed that higher concentrations of soluble Ad3/7-FK (150 and 512 
89 nM, respectively) were required to reach equilibrium binding at high CD46ex-huFc 513 
density levels compared to Ad11/35-FK (18.75 nM) (Fig. 5A-D).  At equilibrium 514 
binding, both Ad3/7-FK and Ad11/35-FK slowly dissociated, indicative of stable 515 
complexes.  At low CD46ex-huFc density, the Ad11/35-FKs and to a very low extent 516 
also Ad7-FK but not Ad3-FK showed detectable binding.  The absolute binding 517 
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values Rmax varied by factors of 2-3 between Ad3 and Ad7-FK, and Ad11 and Ad35-518 
FK, as well as different technical replicas of the experiments, possibly reflecting 519 
different degrees of FK purities and chip conditions. 520 
Combined binding kinetics and affinity measurements were carried out for each of 521 
the four FKs.  For this, we used three independent measurements in the range of 522 
0.27, 0.82, 2.47, 7.41, 22.22 and 66.67 nM, and two different high-density CD46 523 
biosensor chips of 2,630 RU and 1,121 RU.  Both biosensor chips gave similar 524 
results (Fig. 5E-H, sTable 1).  In addition, Ad3-FK binding was found to be 525 
independent of the flow rate at the standard flow rate of 30 µl/min and an increased 526 
flow rate of 55 µl/min, excluding the possibility that the binding reactions were 527 
influenced by mass transfer effects (41).  The values for the kinetic rate constants 528 
were highly reproducible for the individual FKs, with low standard errors for the 529 
association and dissociation constants (see Fig. 5E-H, sTable 1).  The kinetics and 530 
binding data could be best fitted to a two-stage reaction model rather than 531 
monophasic, or trivalent binding models (see equations in supplemental Methods).  532 
Modeling of the measured association and dissociation rate constants and R values 533 
was carried out based on global fittings for ka1, ka2, kd1 and kd2, and local calculations 534 
of Rmax, and % χ2/Rmax.  All % χ2/Rmax values were below 5%.  The average apparent 535 
KD values (Table 4) were not significantly different for Ad3-FK (2.48 x10-10 M) and 536 
Ad7-FK (3.70 x10-10 M), whereas the apparent KD for Ad11-FK and Ad35-FK were 10-537 
15-fold lower (P=0.002/0.0669 for Ad3/7 compared to Ad11, and P=0.0014/0.063 for 538 
Ad3/7 versus Ad35) and amounted to 2.46 x10-11 and 1.78 x10-11 M, respectively.  539 
Thus, the 10-15-fold difference between the apparent KD values for Ad3/7 and 540 
Ad11/35 at high CD46 densities deviated considerably from the 2,000-fold 541 
differences of KD reported for the monovalent CD46 binding to Ad7-FK and Ad11-FK 542 
(48).  Since the measurements were performed using similar set ups, this suggests 543 
that at high surface densities of CD46, trimeric FK interacts with two or even three 544 
CD46 binding sites and the resulting avidity effects overcome low affinity restrictions 545 
of single FK–CD46 interactions. 546 
547 
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Discussion 548 
The data obtained in this study suggest that both, DSG-2 and CD46 can serve 549 
simultaneously as Ad3 receptors and that avidity effects allow the low affinity CD46-550 
binders Ad3/7-FK to attach to CD46 for infectious entry.  Conspicuously, several Ad 551 
serotypes have been reported to utilize more than one attachment receptor, which 552 
could be part of an evolutionary strategy to increase viral fitness (76).  For example, 553 
the species D Ad9 with a very short fiber was found to allow fiber-independent 554 
binding of the penton base directly to integrins, if integrins were present in sufficient 555 
amounts (51).  In integrin-low cells, the virus instead used CAR for productive 556 
infection.  Our findings that species B1 adenoviruses use avidity to bind to the CD46 557 
receptor has important consequences for tropism and possibly evolution of the 558 
species B1 viruses, where viral receptor-binding proteins are under selective 559 
pressure and undergo constant variation to evade neutralization by antibodies (23, 560 
47).  High affinity binding could, for example, represent a dead-end in evolutionary 561 
terms, as such viruses would be constrained to a single receptor.  Weak affinity to a 562 
receptor could be essential for gaining access to new attachment receptors. 563 
 564 
Avidity captures low affinity interactions 565 
Viruses use multiple binding strategies, characterized by a broad range of affinity 566 
interactions when analyzed for single binding interaction sites (22, 73).  Viruses with 567 
low affinities include, e.g., influenza virus with millimolar affinity for sialic acid, and 568 
micromolar affinities for rhinovirus attachment to intercellular adhesion molecule-1, 569 
echovirus to decay-accelerating factor, or reovirus to junction adhesion molecule (2, 570 
6, 28, 62).  Biologically important binding of viruses to low affinity receptors occurs, 571 
when virus particles expose multiple binding sites.  This allows for avidity effects and 572 
increases overall affinity.   573 
Avidity is characterized by a synergistic (and not additive) combination of individual 574 
bond affinities, which largely depends on the structure and geometry of the involved 575 
molecules (36).  For example, in the case of an IgG with a valency of two, avidity can 576 
lead to a strong increase of overall affinity, when compared to corresponding 577 
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monovalent Fab fragments (see e.g., an early study from 16).  Particularly strong 578 
avidity effects were also reported for low affinity ErbB2-specific single chain variable 579 
fragment antibodies, where the antibody fragment with the lowest affinity showed 580 
highest avidity increase upon dimerization (44).  Viruses containing trimeric 581 
attachment receptors, such as the reovirus sigma 1 protein or the long and short 582 
fibers of bacteriophage T4, have been suggested to employ avidity mechanisms for 583 
infection (as discussed in 33).  Interestingly, binding of Ad3 to DSG-2 may engage 584 
avidity mechanism, since multimerization of the trimeric Ad3 FK was required for 585 
efficient binding to DSG-2 (69). 586 
 587 
Avidity binding of adenoviruses to CD46 and CAR 588 
Some studies considered Ad3/7 and also Ad14 to be CD46 non-binders due to low 589 
affinity interactions with CD46 (15, 19, 37, 56, 57, 67).  Several lines of evidence, 590 
however, support an avidity-based mechanism for Ad3/7 infection of CD46 positive 591 
cells.  First, Ad3/7 infection correlated with the levels of ectopically expressed CD46, 592 
while Ad11/35 infection was saturated at low CD46 expression levels.  Second, the 593 
binding of species B Ad3/7-FK to immobilized CD46 on a biosensor chip was more 594 
dependent on the receptor density than binding of Ad11/35-FK, and the Ad3/7-FK 595 
binding had only 10-15 fold lower apparent affinity than Ad11/35-FK.  Third, cross-596 
linking of soluble CD46 increased its blocking effect on Ad3/7 infection in human 597 
A549 cells and CHO-CD46 cells.  Fourth, soluble Ad3/7-FKs inefficiently blocked 598 
Ad3/7 infection of CHO-CD46 cells, unlike Ad11/35-FKs, which efficiently blocked all 599 
four tested B serotypes, confirming that Ad3/7 FKs bind with lower affinity to CD46 600 
than Ad11/35 FKs.  These data support and extend earlier binding site mapping 601 
studies, which showed that Ad3/7 engage CD46 through similar surfaces as species 602 
B2 Ad11/35 (13).  In support of this, the recent SPR studies by Persson et al. 603 
revealed a broad variation of CD46 binding affinities, and the authors concluded that 604 
Ad7/11/14/35 are capable to bind to the same epitopes on CD46 (48).  All these data 605 
are in accordance with the observations that both the low affinity CD46 binder Ad3 606 
and the high affinity binder Ad35 use virtually identical pathways to infect human cells 607 
that are CD46-positive (1, 24).  Notable, avidity mechanisms may also allow the 608 
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species B Ad16 to use CD46 for productive infection by increasing the affinity to 609 
CD46 by 70-fold compared to Ad11 (47). 610 
Similar to the species B serotypes, also the CAR-tropic species C Ad serotypes have 611 
a broad spectrum of affinities to CAR over nearly 3 orders of magnitude, ranging from 612 
the low affinity binder Ad9 to the high affinity binder Ad5 (25).  In addition, avidity 613 
effects could be measured by an increase of FK affinity from about 25 nM for 614 
monomeric immobilized Ad2 FK to 1 nM for multivalent immobilized CAR in SPR 615 
assays employing minimal-sized proteins produced in E.coli (33).  The avidity-driven 616 
multivalent binding reaction to immobilized high density CAR (200 RU equivalent to 617 
our CD46 high density chips) could be fitted to a trivalent binding model.  We thus 618 
consider it likely that many different Ads use avidity binding for attachment and 619 
possibly entry into cells.  620 
Avidity effects for Ad–receptor interactions can occur at two levels.  The trivalent FK 621 
protein can increase the overall affinity compared to a monovalent protein.  In 622 
addition, the 12 fiber trimmers on the virus may simultaneously form multiple contact 623 
points with the cell surface.  Both of these mechanisms can contribute to increase the 624 
overall affinities of the virus particle to its receptor.  Importantly, in the case of the 625 
CAR binders Ad2/5, CAR clustering leads to viral surfing motions on the cell surface 626 
and triggers viral uncoating assisted by confined motions of the viral coreceptor alpha 627 
v integrin (5).   628 
 629 
Apparent KD values of species B FKs to divalent CD46 differ from KD values 630 
with monovalent soluble CD46 631 
Avidity effects are strongly dependent on the valency of the ligand, as observed for 632 
example with binding of dimeric ephrin-A5 ligand to dimerized EphA3 receptor (45).  633 
Accordingly, the measured KD values for FKs to our CD46ex-Fc were about 5 logs 634 
lower for the Ad3/7-FKs, and 3 logs lower for Ad11/35 compared to the KD values for 635 
the monovalent CD46-SCR I-II interactions published by others (10, 47, 48, 71, 72).  636 
Further to the valency difference, the CD46-SCR I-II protein used in other studies 637 
was produced in mutant CHO cells and contained homogenous, high mannose N-638 
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linked carbohydrates (48).  Our CD46 protein consisted of the entire extracellular 639 
domain plus a dimerizing Fc portion, and was produced in normal BHK cells allowing 640 
for complex O- and N-linked glycosylations (60).  Interestingly, the extended CD46 641 
SCR I-IV domain has a somewhat different binding mode to Ad11-FK, as the contact 642 
site did not include the IJ loop described for CD46 SCR I-II interaction (50).  We 643 
suggest that the dimeric nature of our CD46ex-huFc explains why the binding of the 644 
Ad3/7/11/35 FKs fit better to a two-stage reaction model than to trivalent binding 645 
models, described earlier for Ad2-FK interaction with CAR (33).  This is based on 646 
comparison of the different affinities under our standard conditions.  We conclude 647 
that the observed KD differences between the monovalent and trivalent affinities of 648 
the Ad3/7/11/35-FKs are based on avidity binding.   649 
 650 
Virus–receptor affinity versus receptor density  651 
A recent systematic study with retargeted MV vectors has shown that viruses 652 
displaying HER2/neu-specific single-chain variable fragment antibodies had high 653 
avidity and cell killing ability due to dozens of single chain molecules in the viral 654 
envelope, even if their single affinities were in the low micro-molar range (21).  This 655 
study noticed a receptor threshold level for productive infection, together with an 656 
inverse correlation of attachment receptor affinity and receptor density requirements 657 
for infection.  In particular, supra-threshold affinities did not further enhance the 658 
efficiency of MV infection, which corresponds well with our results for high affinity 659 
CD46 binders Ad11/35.  It also fits well with another observation showing that Ad35-660 
FK mutants with either 4-fold or 60-fold higher affinity at the monovalent interaction 661 
level did not yield higher transduction levels, regardless of the cellular CD46 receptor 662 
density (72).   663 
With the FK neutralization experiments in CHO-CD46#2 expressing cells, we noticed 664 
that Ad3/7-FKs did not efficiently compete against the binding of corresponding virus 665 
particles, in contrast to Ad11/35-FKs, which efficiently blocked Ad3/7/11/35.  This is 666 
due to low affinity of Ad3/7-FK for CD46, since binding of the different species B Ads 667 
is restricted to CD46 in these cells (13, 60).  This conclusion was corroborated by the 668 
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findings that soluble CD46ex-huFc inefficiently inhibited binding of Ad3/7 to the cells, 669 
in agreement with weak blocking efficiency of Ad3/7 by soluble CD46 (13, 67), and 670 
also by soluble monovalent CD46 for MV infection (58).  Ad3/7 inhibition was, 671 
however, strongly enhanced by cross-linking the CD46ex-huFc protein (Fig. 3), 672 
suggesting that cross-linked CD46ex-huFc mimics the multiple interaction situation 673 
when the virus contacts the cell surface.  Similarly, CD46 cross-linking by genetically 674 
fusing the CD46 ectodomain to the octamer oligomerization domain of C4b binding 675 
protein resulted in a 2 log enhanced MV neutralizing activity in vitro and in vivo due to 676 
enhanced virus binding (8).   677 
These data suggest that the receptor density is of key importance not only for 678 
interaction of CD46 with trimeric FK, but also the multivalent virus particle.  Together 679 
or alone, this gives rise to avidity effects, which allow Ad3/7 to infect cells expressing 680 
sufficient levels of CD46 (13, 20, 60).  The lack of Ad3/7 infection in CHO-CD46 cells 681 
reported by other groups is most likely due to low CD46 expression levels, and assay 682 
systems of low sensitivity or limited dynamic range (15, 18, 37, 57, 67).   683 
 684 
Mechanistic implications of desmoglein-2 and CD46 as receptors for Ad3/7  685 
Our DSG-2/CD46 combinatorial loss-of-function experiments in A549 and 16HBE14o 686 
cells significantly enhanced the reduction of cell surface binding and infection of Ad3 687 
by ~ 10% compared to DSG-2 interference alone, showing that CD46 has a 688 
significant role for infectious Ad3 entry in these cells.  We suggest that in non-689 
polarized A549, 16HBE14o or HeLa cells (70) expressing both receptors, DSG-2 690 
functions as a major attachment receptor for Ad3.  This could be due to a lower 691 
affinity/avidity of Ad3 to CD46 compared to DSG-2, or to higher levels of DSG-2 692 
compared to CD46.  In other human cells the CD46 contribution may be more 693 
pronounced depending on the expression levels of the receptors.  This is supported 694 
by our data from rodent CHO-CD46 and human M010119 melanoma cells lacking 695 
DSG-2, where Ad3/7 uses CD46 as functional receptor.   696 
For oncolytic therapies with HAdVs, it will be important to determine the DSG-2 697 
expression levels among human cells and tissues in health and disease and put 698 
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these data in relation to CD46 expression.  In particular, it is conceivable that DSG-2 699 
and CD46 act independently as Ad3/7 receptors.  For example in polarized cells, 700 
DSG-2 is a component of the cell-cell adhesion structure of intercellular junctions 701 
(26).  CD46 is present on apical and basolateral surfaces (3, 59, 64).  Apical CD46 702 
may be an initial docking site for species B HAdVs, and lead to the activation of 703 
DSG-2 from the lateral cell-cell contact sites.  Interestingly, a library screening 704 
experiment of fiber-pseudotyped Ads revealed relatively high levels of apical 705 
transduction of Caco-2 cells by Ad7 and Ad35, despite low levels of virus attachment 706 
to the apical membrane (29).  Speculatively, apical infections may be exacerbated by 707 
cytokine-mediated relocalization of CD46 and DSG-2 to the apical surface upon 708 
cytokine signaling from immune cells, as demonstrated for species C receptors CAR 709 
and alpha v beta 3 integrins (35).  This may lead to a situation where DSG-2 and 710 
CD46 complement each other, for example by physical interactions.  Possibly, DSG-711 
2 or another molecule function as a tethering factor for CD46, and prolong the half-712 
life of CD46 on the plasma membrane thereby increasing the CD46 avidity effects.  713 
Clustering of CD46 may occur in particular lipid domains (66) or in the vicinity of 714 
integrins or tetraspanins (34).  In this scenario, lipids, integrins or tetraspannins could 715 
be modulators for CD46 function, and may not be required for Ad3 infection, if the 716 
CD46 levels were sufficiently high.  Clustering of CD46 by antibodies or Ad3/35 717 
facilitates CD46 internalization by clathrin-mediated endocytosis or macropinocytosis, 718 
followed by endosome lysis in the case of Ad3/35 and virus particle penetration from 719 
endosomes to the cytosol (1, 9, 24). 720 
721 
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34 
Legends to figures 998 
Fig. 1.  Loss-of-function studies for individual contribution of CD46 and DSG-2 to Ad3 999 
infection.  (A, B) Inhibition of Ad3 (A) and Ad35 (B) binding to A549 cells by anti-1000 
CD46 and DSG-2 antibodies.  A549 cells were incubated with the indicated 1001 
concentrations of CD46 (MEM258), DSG-2 (6D8 and 8E5), a mix of both types of 1002 
antibodies, control CAR antibodies or PBS, followed by the addition of atto-488-1003 
labeled Ad3 or Ad35 at 4°C.  Virus binding was assesed by cytofluorometric analysis.  1004 
The data were normalized to the amounts of virus bound when using PBS.  Mean 1005 
values and standard deviations of triplicates from one representative experiment are 1006 
shown.  (C-H) Effect of siRNA-mediated down-regulation on virus infection in A549 1007 
(C-E) and 16HBE14o cells (F-H). (C, F) Cells were transfected with the indicated 1008 
siRNAs resulting in specific down-regulation of CD46 and DSG-2, but not of 1009 
unrelated CAR.  Shown is one representative analysis.  (D, G) Binding of atto488-1010 
labeled Ad2 (control), Ad3 and Ad35 to siRNA-transfected cells was assessed as 1011 
described above.  (E, H) Transduction of siRNA-transfected cells with eGFP 1012 
expressing control Ad5, Ad3 and Ad35 vectors at 500 vp/cell.  eGFP expression 1013 
values were analyzed two days p.i. by flow cytometry and are expressed as mean 1014 
fluorescence intensity values (MFI).  1015 
 1016 
Fig. 2.  Binding and transduction of adenovirus species B viruses in CD46 gain-of-1017 
function cells negative for DSG-2.  (A) For Ad binding assays, 5 x 105 of human A549 1018 
cells, and the different rodent CHO-CD46 cells were incubated on ice with 1,000 vp 1019 
of the indicated [3H]-labeled species B serotypes.  After incubation for 2 h, the cells 1020 
were washed and cell-associated radioactivity was determined.  Mean values and 1021 
standard deviations of triplicates from one representative experiment are shown.  1022 
Asterisks indicate here and in the experiments below the level of significance 1023 
(*P<0.05; **P<0.005; ***P<0.0005 for comparisons of corresponding Ad binding 1024 
(infection) in parental CHO versus CD46-transfected cells).  (B) Transduction assays 1025 
of human A549, parental CHO and CHO-CD46 expressing cells.  105 cells were 1026 
incubated with eGFP expressing Ad3, Ad7, Ad11, and Ad35 vectors at increasing 1027 
virus concentrations of 10, 100, and 1,000 vp/cell.  eGFP expression was analyzed 1028 
35 
two days p.i. by flow cytometry and are expressed as MFI.  (C) Transduction assays 1029 
of human parental and stable CD46-transfected M010119 melanoma cells.  Cells 1030 
were transduced and tested as described above.  Background fluorescence intensity 1031 
for uninfected M010191-eGFP-CD46 cells was higher due to the eGFP-tagged CD46 1032 
in these cells. 1033 
 1034 
Fig. 3.  Cross-linking of CD46ex-huFc strongly increases blocking of Ad3/7 infection 1035 
in CHO-CD46#2 and A549 cells.  (A) CHO-CD46#2 cells or (B) A549 cells were pre-1036 
incubated for 1 h in the cold using the indicated concentrations of adapter CD46ex-1037 
huFc alone or in combination with a 2-fold increase series of goat-anti human Fc 1038 
antibody.  Following addition of the different eGFP-expressing vectors for another 1039 
1 h, cells were washed and analyzed 48 h p.i.  Asterisks indicate the level of 1040 
significance (*P<0.05; **P<0.005; ***P<0.0005 for comparisons of corresponding Ad 1041 
infection using CD46ex-huFc versus control CARex-huFc of sFig. 2). 1042 
 1043 
Fig. 4.  Inhibition of Ad3-, Ad7-, Ad11-, and Ad35-eGFP transduction in CHO-1044 
CD46#2 and A549 cells by recombinant Ad fiber knobs.  Cells were pre-incubated for 1045 
1 h in the cold using a 5-fold dilution series of the individual FK proteins, followed by 1046 
addition of the different eGFP-expressing vectors for another 1 h. (A) For CHO-1047 
CD46#2 cells, the viral inputs amounted to 29,600, 8,200, 657, and 1,088 vp / cell for 1048 
Ad3-, Ad7-, Ad11-, and Ad35-eGFP, respectively.  The virus input concentrations had 1049 
been determined in preceding experiments and were chosen such that the unblocked 1050 
transgene expression values amounted to fluorescence intensity values of about 200.  1051 
eGFP analysis was performed 48 h p.i..  FKs are color-coded as follows: Ad5-FK in 1052 
green, Ad3-FK in red, Ad7-FK in purple, Ad11-FK in cyan and Ad35-FK in dark blue.  1053 
(B) For A549 cells virus inputs amounted to 14,800, 8,200, 1,314, 2,540 and 2,825 1054 
vp/cell for Ad3-, Ad7-, Ad11-, Ad35-, and Ad5-eGFP, respectively.  Otherwise, the 1055 
procedure was the same as above. 1056 
 1057 
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Fig. 5. Subtracted SPR sensograms for Ad3-, Ad7-, Ad11- and Ad35-FK interacting 1058 
with CD46.  Soluble receptor CD46ex-huFc was immobilized on a CM5 chip at high 1059 
density in Fc2 (2,630 RU, 1, 3) and low density in Fc4 (345 RU, 2, 4).  Control 1060 
CARex-huFc was immobilized at high density in Fc1 (3,431 RU, 1, 3) and low density 1061 
in Fc3 (278 RU, 2, 4).  (A) to (D), FK analytes were injected over the sensor surface 1062 
at 18.75 and 150 nM concentrations for Ad3-FK (A), Ad11-FK (C) and Ad35-FK (D), 1063 
and at 11.07 and 88.59 nM for Ad7-FK (B), respectively.  Association times were 1064 
either 240 or 280 s.  (E) to (H), overlay of analyte responses for Ad3-, Ad7-, Ad11- 1065 
and Ad35-FK at different concentrations.  Measurements were performed using the 1066 
CD46 high-density 2,630 RU CM5 chip.  Serial concentrations of 0.27, 0.82, 2.47, 1067 
7.41, 22.22 and 66.67 nM of Ad3-FK (E), Ad7-FK (F), Ad11-FK (G), and Ad35-FK (H) 1068 
were injected in HBS-P+ buffer at 30 μl/min under contact time of 300 s and 1069 
dissociation time of 3,600 s (for better visibility only four of the six binding curves are 1070 
shown).  Data evaluation was fitted globally by two-stage reaction model with Biacore 1071 
T100 evaluation software, and resulting kinetics/affinity results are listed in sTable 1 1072 
and summarized in Table 4. 1073 
1074 
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Table 1.  Species B serotype-mediated eGFP transgene expression in different 1075 
CHO-CD46-expressing cells compared to parental CHO and human A549 cells 1076 
 eGFP expression levels: Fold change compared to CHO
a 
 CHO-CD46#6 CHO-CD46#1 CHO-CD46#2 
Ad3-eGFP 18 55 192 
Ad7-eGFP 37 85 354 
Ad11-eGFP 40 88 79 
Ad35-eGFP 60 106 96 
 
eGFP expression levels: % of A549 expressionb 
CHO CHO-CD46#6 CHO-CD46#1 CHO-CD46#2 
Ad3-eGFP 0.24 19 60 211 
Ad7-eGFP 0.23 21 50 202 
Ad11-eGFP 1.03 49 105 95 
Ad35-eGFP 2.66 177 305 284 
 eGFP expression levels: vp/cell needed to reach MFI 100c 
 CHO-CD46#6 CHO-CD46#1 CHO-CD46#2 A549 
Ad3-eGFP 8,207 (27) 2,597 (16) 717 (4.2) 1,513 (2.7) 
Ad7-eGFP 2,919 (9.5) 1,210 (7.3) 267 (1.57) 602 (1.1) 
Ad11-eGFP 634 (2.1) 291 (1.8) 314 (1.8) 329 (0.6) 
Ad35-eGFP 307 165 170 562 
 1077 
a Ratio of eGFP mean fluorescence intensity levels from CD46-expressing cell line to parental CHO 1078 
were determined for 1,000 vp/cell input.  1079 
b Percentage of eGFP mean fluorescence intensity levels of CD46-expressing cells relative to A549 1080 
cells were determined for 1,000 vp/cell input.  1081 
c Regression lines were calculated for the eGFP expression levels; numbers in parentheses 1082 
correspond to fold-higher virus concentration input compared to Ad35-eGFP.  1083 
1084 
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Table 2.  eGFP transgene expression analysis in M010119 and M010119-eGFP-1085 
CD46#8 cells 1086 
 
eGFP expression levels: Fold 
change compared to 
M010119a 
eGFP expression levels: vp/cell needed to reach 
MFI 100b 
M010119 
M010119-eGFP-
CD46#8 
Ad3-eGFP 86 34,513 271 (127) 
Ad7-eGFP 26 4,695 91 (52) 
Ad11-eGFP 2.1 344 110 (3.1) 
Ad35-eGFP 2.3 258 130 (2.0) 
 1087 
a Ratio of eGFP mean fluorescence intensity levels from M010119-eGFP-CD46#8 cells to parental 1088 
M010119 cells were determined for 1,000 vp/cell input.  1089 
b Regression lines were calculated for the eGFP expression levels.  Numbers in parenthesis 1090 
correspond to fold-enhancement of transduction efficiency in M010119-eGFP-CD46#8 cells compared 1091 
to M010119 cells, based on MFI 100 values. 1092 
1093 
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Table 3.  Inhibition of Ad3/7/11/35-eGFP and Ad5-eGFP-mediated reporter 1094 
expression by fiber knob cross-competition.  1095 
Competitor Cells 
% Inhibition of eGFP expression a 
Ad3-eGFP Ad7-eGFP Ad11-eGFP Ad35-eGFP Ad5-eGFP 
Ad3-FK 
CHO-CD46 40 7 18 -3 nd 
A549 93 78 28 18 17/-9 
Ad7-FK 
CHO-CD46 86 81 21 -10 nd 
A549 95 87 4 -18 2/12 
Ad11-FK 
CHO-CD46 99 98 99 97 nd 
A549 93 95 99 100 -10/-6 
Ad35-FK 
CHO-CD46 98 85 97 96 nd 
A549 74 56 99 99 -1/-7 
Ad5-FK 
CHO-CD46 1 -35 16 0 nd 
A549 24 9 -21 29 26/97 
 
 
FK concentration for 50% inhibition (ng/ml) b 
Ad3-eGFP Ad7-eGFP Ad11-eGFP Ad35-eGFP Ad5-eGFP 
Ad3-FK 
CHO-CD46 nd nd nd nd nd 
A549 25 23 nd nd nd 
Ad7-FK 
CHO-CD46 169 2’690 nd nd nd 
A549 17 31 nd nd nd 
Ad11-FK 
CHO-CD46 14 21 22 37 nd 
A549 31 87 13 14 nd 
Ad35-FK 
CHO-CD46 5 63 14 26 nd 
A549 470 4,459 33 5 105 
 1096 
aData correspond to inhibitions obtained using 5,000 ng/ml FK concentration in Fig. 2C, D.   1097 
bData were calculated by applying regression lines to values in Fig. 2C, D.  nd: not determined.  1098 
1099 
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Table 4. Summary kinetics/affinity analyses of Ad-FKs binding to immobilized 1100 
CD46ex-huFc 1101 
 ka1 (M-1s-1)  kd1 (s-1) ka2 (s-1) kd2 (s-1) KD ± SEM (M) 
Ad3-FK 2.30 x105 6.88 x10-4 2.01 x10-3 1.76 x10-4 2.48 ± 0.27 x10-10 
Ad7-FK 1.44 x105 4.19 x10-4 1.94 x10-3 1.99 x10-4 3.70 ± 1.38 x10-10 
Ad11-FK 9.27 x105 3.27 x10-4 5.41 x10-3 1.60 x10-4 2.46 ± 1.50 x10-11 
Ad35-FK 3.08 x106 4.66 x10-4 1.25 x10-3 1.29 x10-4 1.78 ± 1.04 x10-11 
 1102 
Values are averages of three individual measurements  1103 
 1104 
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Kinetic/affinity analysis and fitting procedure for SPR 3 
Kinetic/affinity analysis of FK binding to immobilized CD46 was performed using 4 
three models in combination with the Biacore T100 evaluation software version 2.0.3.  5 
A first included a 1:1 fitting model provided by the Biacore T100 evaluation software 6 
itself, which failed to describe the obtained binding data satisfyingly.  Second, two 7 
trivalent models were tested and included the equations described by Lortat-Jacob et 8 
al. (2) and a variation of the equations described by Fournel et al. (1) (Johan 9 
Hoebeke, personal communication).  Both trivalent models resulted in reasonable 10 
good fitting for Ad11- and 35-FK to immobilized CD46 judged by χ2 values, but they 11 
showed relatively large errors for Ad3- and Ad7-FK binding kinetics.  Third, a two-12 
stage reaction model was applied to globally fit the binding data, which provided the 13 
lowest χ2 values for all four FK binding reactions.  In this model, analyte (A) binds to 14 
ligand (B) to form the complex AB, then complex AB changes to ABx, which cannot 15 
dissociate directly to A+B.  The net reactions are described by equations 1–6, where 16 
σkd1, σkd2, σka1, and σka2 are standard deviation for individual kd1, kd2, ka1, and ka2, 17 
respectively.  σKD is the standard deviation for overall KD.   18 
 19 
20 
2 
Legends to supplemental figures 20 
 21 
SFig. 1. Flow cytometry profiles of CD46 and DSG-2 expression.  CD46 was 22 
analyzed in A549 human lung cells, parental rodent CHO and three different stable 23 
and clonal CHO-CD46 transfectants with increasing CD46 levels (A), in human 24 
16HBE14o bronchial epithelial cells (C), or in parental M010119 and stable 25 
transfected M010119-eGFP-CD46#8 cells (E).  Numbers after slash indicate MFI 26 
values resulting from utilizing the MCI20.6 anti-CD46 antibody (A, C), or GB24 anti-27 
CD46 (stains both, endogenous and eGFP-tagged CD46) (E).  Controls using isotype 28 
antibody were in the range from 0.8 to 1 (not shown).  DSG-2 was analyzed in A549 29 
cells and in parental M010119 cells (B), in 16HBE14o cells (D) and stable transfected 30 
M010119-eGFP-CD46#8 cells (F) with 6D8 anti-DSG-2 antibody. 31 
 32 
SFig. 2.  Control for cross-linking experiment shown in Fig. 3 with CARex-huFc 33 
replacing CD46ex-huFc.  (A) CHO-CD46#2 cells or (B) A549 cells were pre-34 
incubated for 1 h in the cold using the indicated concentrations of adapter CARex-35 
huFc alone or in combination with a 2-fold increase series of goat-anti human Fc 36 
antibody.  Following addition of the different eGFP-expressing vectors for another 37 
1 h, cells were washed and analyzed 48 h p.i.   38 
 39 
SFig. 3.  Analysis of recombinant Ad-FK and CD46ex-huFc proteins.  (A, B) 40 
Individual FK proteins were produced using the Baculovirus expression system.  41 
Purified FK proteins from Ad3, Ad5, Ad7, Ad11, and Ad35 were analyzed by either 42 
12.5% reducing PAGE and sypro ruby red staining (A), or by 10% native PAGE and 43 
Coomassie Blue staining (B).  (C) Analysis of recombinant CD46ex-huFc.  Three µg 44 
of purified CD46ex-huFc were analyzed by 10% native PAGE and Coomassie Blue 45 
staining. 46 
 47 
3 
STable 1. Overview kinetics/affinity analysis of Ad-FKs binding to immobilized CD46ex-huFc 48 
Annalyte / RU chip / 
binding experiment 
Flow rate 
(ul / min) ka1 (M
-1s-1)
 a
 kd1 (s
-1) ka2 (s-1) kd2 (s-1) % χ²/Rmax KD (M) 
Ad3-FK / 1121 / 1 55 2.04 x105 (0.0014) 7.11 x10-4 (0.019) 1.97 x10-3 (0.0037) 1.64 x10-4 (0.0022) 0.64 - 1.31 2.68 x10-10 (0.0093) 
Ad3-FK / 1121 / 2 30 1.92 x105 (0.0013) 7.18 x10-4 (0.020) 2.03 x10-3 (0.0037) 1.65 x10-4 (0.0022) 0.66 - 1.28 2.81 x10-10 (0.0101) 
Ad3-FK / 2630 / 3 30 2.93 x105 (0.0035) 6.36 x10-4 (0.019) 2.02 x10-3 (0.0046) 1.98 x10-4 (0.0029) 1.36 - 2.78 1.94 x10-10 (0.0079) 
Ad7-FK / 1121 / 4 30 4.20 x104 (0.012) 3.39 x10-4 (0.059) 3.77 x10-3 (0.036) 5.08 x10-5 (0.061) 0.03 - 0.50 1.07 x10-10 (0.0249) 
Ad7-FK / 2630 / 5 30 2.44 x105 (0.0047) 5.88 x10-4 (0.015) 1.18 x10-3 (0.0035) 2.58 x10-4 (0.0064) 0.44 - 0.93 4.32 x10-10 (0.0195) 
Ad7-FK / 2630 / 6 30 1.44 x105 (0.0046) 3.30 x10-4 (0.011) 8.67 x10-4 (0.048) 2.90 x10-4 (0.015) 0.25 - 0.71 5.72 x10-10 (0.0419) 
Ad11-FK / 1121 / 7 30 9.04 x105 (0.021) 9.86 x10-5 (0.091) 6.96 x10-4 (0.11) 7.57 x10-5 (0.39) 2.86 - 5.05 1.07 x10-11 (0.0531) 
Ad11-FK / 2630 / 8 30 7.96 x105 (0.012) 3.93 x10-4 (0.018) 1.03 x10-3 (0.0054) 1.28 x10-4 (0.01) 0.27 - 3.72 5.47 x10-11 (0.0527) 
Ad11-FK / 2630 / 9 30 1.08 x106 (0.00086) 4.90 x10-4 (0.032) 1.45 x10-2 (0.023) 2.77 x10-4 (0.046) 3.52 - 4.19 8.48 x10-12 (0.199) 
Ad35-FK / 1121 / 10 30 3.54 x106 (0.0088) 2.16 x10-4 (0.015) 1.12 x10-3 (0.0081) 1.06 x10-4  (0.0037) 0.12 - 3.03 5.23 x10-12 (0.0751) 
Ad35-FK / 2630 / 11 30 2.12 x106 (0.0034) 7.96 x10-4 (0.030) 1.33 x10-3 (0.0042) 1.51 x10-4 (0.0049) 0.27 - 3.08 3.85 x10-11 (0.0222) 
Ad35-FK / 2630 / 12 30 3.60 x106 (0.0057) 3.85 x10-4 (0.019) 1.30 x10-3 (0.0061) 1.31 x10-4 (0.0076) 0.16 - 4.76 9.76 x10-12 (0.0833) 
 49 
a values in parentheses are errors of the fitting procedure  50 
 51 
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sFig. 1.  Flow cytometry profiles of CD46 and DSG-2 expression.  CD46 was analyzed in A549 human lung cells, parental rodent CHO
and three different stable and clonal CHO-CD46 transfectants with increasing CD46 levels (A), in human 16HBE14o bronchial epithelial
cells (C), or in parental M010119 and stable transfected M010119-eGFP-CD46#8 cells (E).  Numbers after slash indicate MFI values
resulting from utilizing the MCI20.6 anti-CD46 antibody (A), or GB24 anti-CD46 (stains both, endogenous and eGFP-tagged CD46) (E).
Controls using isotype antibody were in the range from 0.8 to 1 (not shown).  DSG-2 was analyzed in A549 cells and in parental M010119
cells (B), in 16HBE14o cells (D) and stable transfected M010119-eGFP-CD46#8 cells (F) with 6D8 anti-DSG-2 antibody.
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sFig. 2. Control for cross-linking experiment shown in Fig. 3 with CARex-huFc replacing CD46ex-huFc.  (A) CHO-CD46#2 cells or (B) A549
cells were pre-incubated for 1 h in the cold using the indicated concentrations of adapter CARex-huFc alone or in combination with a 2-
fold increase series of goat-anti human Fc antibody.  Following addition of the different eGFP-expressing vectors for another 1 h, cells
were washed and analyzed 48 h p.i.
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sFig. 3.  Analysis of recombinant Ad-FK and CD46ex-Fc proteins.  (A, B) Individual FK proteins were produced using the 
Baculovirus expression system.  Purified FK proteins from Ad3, Ad5, Ad7, Ad11, and Ad35 were analyzed by either 12.5% 
reducing PAGE and sypro ruby red staining (A), or by 10% native PAGE and Coomassie Blue staining (B).  (C) Analysis of 
recombinant CD46ex-huFc.  Three µg of purified CD46ex-huFc were analyzed by 10% native PAGE and Coomassie Blue staining.
